Stifel 401(k) Plan Subject of New $134 Million ERISA Case Over Fund Performance
Stifel Financial Corp. is facing a $134 million class action ERISA lawsuit alleging mismanagement of its 401(k) plan. The suit claims Stifel failed to remove two underperforming funds, the American Century Large Cap Growth Fund and the Artisan Mid-cap Growth Fund, which allegedly cost participants up to $134 million in lost retirement savings since March 2020. This case follows other significant ERISA class action settlements and lawsuits filed by the same firm.
Encompass Health, Enhabit Secure $43.1M Judgement in VitalCaring Case
Encompass Health and Enhabit Inc. have been awarded $43.1 million in a judgement against home health and hospice provider VitalCaring. This ruling mandates that 43% of VitalCaring's profits and future sale proceeds be placed in a trust for Encompass and Enhabit, stemming from allegations of misconduct by VitalCaring's senior executives who previously worked for Encompass Health. The dispute had also paused VitalCaring's acquisition of over 100 home health and hospice locations.
Alliance of companies will help accelerate $50 billion in rural health programs
An alliance of companies including Arcadia, Castlight Health, Covista, Mission Mobile Medical, Telemedicine.com, TruBridge, and Walgreens has formed to help states and local markets spend $50 billion from the federal Rural Health Transformation program. The Alliance for Advancing Rural Healthcare (AARH), formed by Science Applications International Corp. (SAIC), aims to strengthen the rural clinical workforce, modernize health IT systems, and connect patients to care, leveraging AI, data management, and cybersecurity solutions. Each member company brings specialized expertise to address the critical needs of rural communities and support state governments in navigating the complexities of healthcare transformation.
UnitedHealth Group Incorporated $UNH Shares Sold by Synovus Financial Corp
Synovus Financial Corp reduced its stake in UnitedHealth Group (NYSE:UNH) by 24.0% in the third quarter, selling 8,410 shares and retaining 26,641 shares valued at approximately $9.20 million. Despite this reduction and recent price target cuts from several firms, UnitedHealth Group maintains a "Moderate Buy" consensus rating with an average target price of $372.13. The company reported strong Q1 earnings, beating EPS estimates, and provided positive FY2026 guidance, while trading near $286 with a market capitalization of about $259 billion.
Scientific Evidence Demonstrates OPTAVIA®’s Metabolic Health Benefits, Opening the Door to Qualified HSA/FSA Clients
Medifast announced that its OPTAVIA metabolic health system is now eligible for reimbursement through Health Savings Accounts (HSA) and Flexible Spending Accounts (FSA), allowing clients to save up to 40% on program costs. This move is significant as over 90% of U.S. adults are metabolically unhealthy, and OPTAVIA's science-backed approach, including Metabolic Synchronization™, aims to reverse metabolic dysfunction by reducing visceral fat and preserving lean muscle mass. Medifast plans to launch new products in 2026 to further support metabolic health, reinforcing its commitment to scientific solutions and comprehensive behavioral support.
Persistent Asset Partners Ltd Makes New $4.17 Million Investment in UnitedHealth Group Incorporated $UNH
Persistent Asset Partners Ltd has made a significant new investment of $4.17 million in UnitedHealth Group Incorporated, purchasing 12,063 shares. This stake represents about 2.9% of the firm's investment portfolio, making it their third-largest holding. The article also details other institutional investors' recent activities in UnitedHealth Group and provides an overview of the company's stock performance, financial metrics, and analyst ratings.
Pool Corporation $POOL Stake Lessened by Ontario Teachers Pension Plan Board
Ontario Teachers Pension Plan Board significantly reduced its stake in Pool Corporation (NASDAQ:POOL) by 87.8% during the third quarter, selling 5,894 shares and holding 818 shares valued at $254,000. This comes as other institutional investors, including Berkshire Hathaway Inc., Norges Bank, and Worldquant Millennium Advisors LLC, either increased their holdings or acquired new stakes in the company. Analysts currently have a "Hold" consensus rating on Pool Corporation with a target price of $311.13, following a mix of upgrades, downgrades, and price target adjustments.
Sanford Heisler Sharp McKnight Files $134 Million ERISA
Sanford Heisler Sharp McKnight has filed a $134 million ERISA class action lawsuit against Stifel Financial, Corp., alleging mismanagement of its 401(k) Plan. The suit claims Stifel breached fiduciary duties by keeping two underperforming funds, American Century Large Cap Growth Fund and Artisan Mid-cap Growth Fund, in the plan for over a decade, costing employees and retirees significant retirement savings. The firm asserts that the poor investment performance of these funds has resulted in up to $134,000,000 in losses for the plan's 10,000 participants since March 1, 2020.
39,650 Shares in UnitedHealth Group Incorporated $UNH Purchased by Compass Wealth Management LLC
Compass Wealth Management LLC recently acquired 39,650 shares of UnitedHealth Group (NYSE:UNH) valued at approximately $13.69 million, making it their 14th largest holding. Other institutional investors like Geode Capital Management and Norges Bank have also significantly increased their positions in the healthcare conglomerate. UnitedHealth Group reported strong Q3 earnings, surpassing analyst estimates, and analysts currently hold a "Moderate Buy" consensus rating for the company with an average target price of $372.13.
Fiera Capital Corp Sells 50,983 Shares of UnitedHealth Group Incorporated $UNH
Fiera Capital Corp significantly reduced its stake in UnitedHealth Group (NYSE:UNH) by selling 50,983 shares, decreasing its holdings by 5.8% to 823,084 shares valued at $284.2 million. Despite this sale and some analyst price target trims, UNH maintains a consensus "Moderate Buy" rating with an average target of $372.13. The healthcare conglomerate also reported quarterly earnings that beat estimates, with revenues slightly below expectations but showing a 12.3% year-over-year increase.
The Resilience of a Healthcare Titan: A Deep Dive into UnitedHealth Group (UNH) in 2026
UnitedHealth Group faces a pivotal year in 2026 as it navigates the fallout of a major 2024 cybersecurity breach, regulatory antitrust probes, and shifting Medicare reimbursement models. Under the returned leadership of CEO Stephen J. Hemsley, the company is pivoting toward AI-driven operational efficiency and value-based care to stabilize its market position after a significant stock correction.
Bundled Pay Management Software Analysis Report 2026-2035: A $7.25+ Billion Market by 2030 with UnitedHealth, McKesson, Oracle, Tata Consultancy Services Leading
The bundled pay management software market is projected to grow significantly from $3.08 billion in 2025 to $7.29 billion by 2030, driven by the complexities of payroll regulations, HR digital tool adoption, and the need for integrated systems. Key factors include AI-enabled automation, cloud-based solutions, real-time compliance, and advanced analytics. North America currently leads the market, with Asia-Pacific anticipated as the fastest-growing region.
The Zacks Analyst Blog UnitedHealth, Honeywell , Shopify and Optex Systems
This Zacks Analyst Blog features research reports on UnitedHealth Group Inc. (UNH), Honeywell International Inc. (HON), Shopify Inc. (SHOP), and micro-cap Optex Systems Holdings, Inc. (OPXS). It reviews their recent performance, financial highlights, and challenges. The article also provides a general overview of Zacks' research offerings including the "Research Daily" and "Ahead of Wall Street" articles.
UnitedHealth stock edges up near $290 as Medicare Advantage shakeout returns to spotlight
UnitedHealth (UNH) stock edged up by 0.5% to $289.57, performing better than the general U.S. market, as the challenges within the Medicare Advantage program are highlighted. A recent study revealed that nearly 3 million Medicare Advantage members were forced to switch plans for 2026 due to insurers exiting markets or reducing options, with UnitedHealthcare accounting for a significant portion of these changes. Investors are closely monitoring the Centers for Medicare & Medicaid Services' (CMS) upcoming decisions on 2027 Medicare Advantage payment rates, alongside ongoing concerns about medical costs and cybersecurity risks affecting UnitedHealth's Change Healthcare unit.
Inmar Intelligence awarded renewed Pharmacy Reverse Distribution agreement with Premier, Inc.
Inmar Intelligence has secured a renewed national group purchasing agreement with Premier, Inc. for Pharmacy Reverse Distribution Services, effective February 1, 2026. This extension allows Premier members to continue benefiting from pre-negotiated pricing and terms for Inmar's services, which aim to simplify returns, enhance compliance, and improve financial recovery for pharmacies. Inmar's Vice President of Healthcare Sales, Anthony Garcia, highlighted the trust placed in their ability to deliver value and maintain regulatory compliance.
UnitedHealth Group Incorporated (UNH) Is a Trending Stock: Facts to Know Before Betting on It
UnitedHealth Group (UNH) is a trending stock on Zacks.com, but its shares have underperformed the S&P 500 and its industry over the past month. The article analyzes UNH's earnings estimate revisions, revenue growth, past performance, and valuation to help investors make informed decisions, noting its Zacks Rank #3 (Hold) suggests it may perform in line with the broader market.
UnitedHealth Group Incorporated (UNH) Is a Trending Stock: Facts to Know Before Betting on It
UnitedHealth Group (UNH) has been a trending stock on Zacks.com, prompting an analysis of factors influencing its performance. Despite a recent decline in stock price, the company's earnings estimates have seen positive revisions for the current and next fiscal year. UnitedHealth holds a Zacks Rank #3 (Hold) and an "A" grade for valuation.
SAIC Launches Alliance to Accelerate State-Led Execution of $50 Billion Rural Healthcare Transformation Program
SAIC has formed the Alliance for Advancing Rural Healthcare (AARH) with seven other organizations to help state governments implement the $50 billion federal Rural Health Transformation (RHT) Program. This initiative aims to address community healthcare challenges in rural areas by integrating capabilities in IT, data, mobile care, education, and pharmacy services. The alliance seeks to translate financial investments into sustainable improvements in access to care, modernized systems, and expanded healthcare workforce capacity across rural America.
Cumberland Partners Ltd Invests $18.38 Million in UnitedHealth Group Incorporated $UNH
Cumberland Partners Ltd has initiated a new position in UnitedHealth Group (NYSE:UNH), purchasing 53,222 shares valued at approximately $18.38 million, making it their 26th largest holding. Institutional investors collectively own 87.86% of UnitedHealth, and analysts currently rate the stock a "Moderate Buy" with a consensus price target of $372.13. The company recently reported Q3 earnings per share of $2.11, beating estimates, and revenue of $113.22 billion, with a FY 2026 earnings per share guidance of $17.75.
IceCure Announces Thomas Hospital of Infirmary Health Installs ProSense®, Becomes First Hospital in Alabama to Offer Breast Cancer Cryoablation
IceCure Medical announced that Thomas Hospital of Infirmary Health in Alabama has installed its ProSense® system, making it the first hospital in the state to offer breast cancer cryoablation. The purchase, funded by the Thomas Hospital Foundation, follows FDA marketing authorization for ProSense® in low-risk breast cancer. This technology provides a minimally invasive option for treating breast cancer by freezing tumors.
UnitedHealth Group Incorporated $UNH Shares Bought by CenterBook Partners LP
CenterBook Partners LP significantly increased its stake in UnitedHealth Group Incorporated (NYSE:UNH) by 164.0% in the third quarter, bringing its total holdings to 10,781 shares valued at $3.72 million. Other institutional investors like Berkshire Hathaway and Carnegie Investment Counsel also adjusted their positions. Analysts currently give UNH a "Moderate Buy" rating with an average price target of $372.13, following its recent earnings report where it beat EPS estimates but slightly missed revenue expectations.
New Haven sues Cigna, CVS Health, UnitedHealth over insulin pricing scheme
The City of New Haven has filed a RICO lawsuit against Cigna, CVS Health, UnitedHealth, and three insulin manufacturers, alleging a scheme to artificially inflate insulin prices between 2010 and 2019. The lawsuit claims that manufacturers set high list prices and funneled secret rebates and administrative fees to Pharmacy Benefit Managers (PBMs) in exchange for preferred formulary placement, leading to inflated costs for self-insured health plans. New Haven is seeking treble damages, disgorgement, punitive damages, and injunctive relief, claiming violations of federal and state antitrust and unfair trade practices acts.
Centene Stock Just Shocked Wall Street – Here’s What You Need to Know
Centene (CNC) has released new earnings and guidance that impact its position in the US health insurance market, particularly regarding Medicaid, Medicare, and ACA plans. The company is actively streamlining its portfolio and improving profit margins, which has significant implications for both consumers' healthcare costs and investors' portfolios. Experts highlight Centene as a core player highly sensitive to political shifts and medical cost trends, making it a "macro story stock" that requires active monitoring.
Centene Stock Just Shocked Wall Street – Here’s What You Need to Know
Centene Corp. (CNC) has released new earnings and guidance that impact the health insurance market, especially for Medicaid and ACA plans. The company is focusing on improving profit margins, stabilizing membership amid Medicaid redeterminations, and cleaning up its portfolio by exiting lower-margin businesses. This strategy could lead to tighter networks and increased digital tools for consumers, while investors are watching for consistent earnings growth and the company's ability to manage medical costs and policy shifts.
Goodpath Launches Direct-to-Employer and Self-Pay Wegovy Access With Novo Nordisk Partnership
Goodpath has partnered with Novo Nordisk to offer direct-to-employer and self-pay options for Wegovy (both injectable and oral versions), aiming to provide employers with transparent GLP-1 pricing and control over subsidy levels. This initiative bypasses traditional PBM structures, integrating Wegovy into a comprehensive "whole-person" weight care model that also addresses comorbidities. Goodpath projects this direct-to-employer program could reduce obesity medication costs by 35% or more while ensuring clinical oversight and support for patients.
Cigna’s Evernorth drops prior authorization for TMS treatment By Investing.com
Cigna's Evernorth, a division of the Cigna Group, will eliminate prior authorization requirements for transcranial magnetic stimulation (TMS) treatment starting March 6, 2026. This policy change will apply to contracted providers for patients with coverage under Evernorth and Cigna Healthcare plans, serving over 18 million lives. The move aims to streamline access to TMS therapy for major depressive disorder and obsessive-compulsive disorder.
Community Health Systems (NYSE:CYH) Releases FY 2026 Earnings Guidance
Community Health Systems (NYSE:CYH) has released its FY 2026 earnings guidance, projecting EPS between -0.600 and 0.000 and revenue of $11.6 billion to $12.0 billion, both falling below analysts' consensus estimates. Following this announcement, CYH shares saw a 2.5% decrease to $3.36, and analysts maintain a "Hold" rating with a consensus price target of $3.60. Institutional investors hold approximately 85% of the stock.
UnitedHealth Group: A Top Healthcare Stock for the Next Decade
UnitedHealth Group's stock has declined over 41% in the past year due to various challenges, including disappointing earnings and potential Medicare changes. Despite this, the company benefits from vertical integration, diverse revenue streams through its insurance and Optum segments, and significant scale effects in the healthcare sector. Wall Street analysts forecast a rise in UNH's stock price, with an average target of $397.82, amidst ongoing adjustments to price targets by firms like Mizuho and JPMorgan.
Humana Expands Florida Primary Care Reach As Shares Trade Below Targets
Humana's CenterWell has acquired MaxHealth, a Florida-based primary care provider, significantly expanding its presence in the state. This acquisition supports Humana's value-based care model for Medicare patients. Despite the strategic move, Humana's shares (NYSE:HUM) are trading below analyst targets and have shown weak performance recently, though Simply Wall St considers them undervalued.
US reexamines Tivic radiation sickness drug that boosted survival in animals
Tivic (Nasdaq: TIVC) announced a follow-up meeting with BARDA on March 10, 2026, to discuss its Acute Radiation Syndrome drug, Entolimod. The meeting will cover clinical data, potential funding, and possible inclusion in the Strategic National Stockpile, following promising animal study results under the FDA Animal Rule. Tivic also highlighted its manufacturing readiness through its subsidiary, Velocity Bioworks.
UnitedHealth Group Stock (UNH) Opinions on Earnings Miss and Medicare Squeeze
This article discusses the market's reaction to UnitedHealth Group's (UNH) recent earnings miss, guidance revision, and the impact of Medicare Advantage rate pressures and cyberattack costs, leading to a significant stock decline. It covers the debate among traders regarding valuation and potential bottom formation, despite the stock remaining a hedge fund favorite due to its defensive qualities and strong cash flow. The article also provides detailed data on insider trading, congressional stock transactions, hedge fund activity, government contracts, and recent analyst ratings for UNH.
Baird's Model Update Suggests Alignment Healthcare, Inc. (ALHC)'s Shares Could Reach $59
Baird has updated its model for Alignment Healthcare, Inc. (ALHC), increasing its price target to $59 from $28 and reiterating an Outperform rating. This suggests a potential 163% upside from its current price. Despite a recent insider sale by CEO John E. Kao, analysts predict profitability for ALHC this year with an expected FY2025 EPS of $0.23.
Bicycle Therapeutics (NASDAQ:BCYC) Upgraded to "Strong-Buy" at Jefferies Financial Group
Bicycle Therapeutics (NASDAQ:BCYC) received an upgrade to "strong-buy" from Jefferies Financial Group, with a current "Moderate Buy" consensus rating and an average price target of $21.11, significantly higher than its current trading price of $5.23. Despite recent insider selling by the CEO and CFO, insiders still retain about 8.5% ownership. Institutional investors have generally increased their holdings, with Principal Financial Group and Acadian Asset Management notably boosting their stakes.
Palladyne AI Accelerates Commercial Push With Appointment of Matt Muta as President of Commercial Business
Palladyne AI (NASDAQ: PDYN, PDYNW) has appointed long-time board member Matt Muta as President, Commercial and Industrial, effective March 2, 2026. This move highlights the company's intensified focus on monetizing its embodied AI software platform, Palladyne IQ, for poly-functional robots in industrial settings. Muta's extensive background in commercializing complex technology at companies like Microsoft and Delta Air Lines is expected to drive enterprise adoption and revenue growth for Palladyne AI.
Drucker Wealth 3.0 LLC Has $2.32 Million Stock Position in UnitedHealth Group Incorporated $UNH
Drucker Wealth 3.0 LLC significantly increased its stake in UnitedHealth Group (UNH) by 130.8% in the third quarter, now holding 6,706 shares valued at approximately $2.32 million. UnitedHealth Group reported strong third-quarter earnings, beating EPS estimates and showing a 12.3% year-over-year revenue increase, with institutional investors owning a substantial 87.86% of the company's stock. Despite a recent stock dip and some analyst price target adjustments, MarketBeat maintains a "Moderate Buy" consensus rating for UNH, with an average target price of $372.13.
Glenview Trust Co Cuts Stake in UnitedHealth Group Incorporated $UNH
Glenview Trust Co has reduced its stake in UnitedHealth Group by 27.6%, selling 4,265 shares, though its remaining 11,166 shares are valued at nearly $3.86 million. Despite this, several major institutions like Norges Bank and Berkshire Hathaway significantly increased their holdings, leading to institutional investors owning 87.86% of the stock. Analysts largely rate UnitedHealth as a "Moderate Buy" with an average target price of $372.13, following a quarter where the company slightly exceeded EPS expectations but narrowly missed revenue forecasts.
UnitedHealth Group Turbulent Year Tests Outlook For 2026 Rebound
UnitedHealth Group (NYSE: UNH) has faced a challenging year marked by elevated healthcare costs, a cyber breach, and litigation, leading to a significant stock decline. Despite leadership signaling a potential rebound in 2026, investors are watching how the company addresses regulatory pressures, data security, and executive conduct questions. The stock is currently trading significantly below analyst targets and Simply Wall St's fair value estimate, with concerns also raised about its high debt level.
Palo Alto Networks cuts annual profit forecast as deal costs bite, shares fall
Palo Alto Networks has reduced its annual profit forecast due to increasing costs associated with recent acquisitions aimed at enhancing its AI capabilities. The cybersecurity company expects significant cash expenditures for its CyberArk and Chronosphere acquisitions. Despite the profit forecast cut, Palo Alto raised its annual revenue outlook, as clients increase investments in security amid rising cyberattacks.
Humana’s CenterWell buys primary care provider MaxHealth
Humana's health services division, CenterWell, has acquired MaxHealth, a primary care provider based in Florida, from private equity firm Arsenal Capital Partners. This acquisition adds 82 clinics (54 owned, 24 affiliated, 4 specialty/ancillary) to CenterWell's portfolio, serving over 120,000 patients and further expanding Humana's primary care business, particularly in value-based care arrangements. The move aligns with Humana's strategy to grow its primary care footprint, though financial details of the deal were not disclosed.
10 Health Care Stocks With Whale Alerts In Today's Session
This article highlights unusual options activity, known as "whale alerts," for ten health care stocks: AbbVie (ABBV), Abbott Laboratories (ABT), Amgen (AMGN), McKesson (MCK), Madrigal Pharmaceuticals (MDGL), Molina Healthcare (MOH), Merck & Co (MRK), Intellia Therapeutics (NTLA), UnitedHealth Group (UNH), and Vertex Pharmaceuticals (VRTX). It details specific call and put option trades, including strike prices, expiration dates, sentiment, and trade volumes, to help traders identify potential opportunities. The report explains key options terminology for better understanding of these alerts.
The IRA could hurt market access for more convenient drugs
The Inflation Reduction Act (IRA) may unintentionally disincentivize Medicare plans from covering more convenient, self-administered subcutaneous (SC) therapies, favoring intravenous (IV) formulations instead. This is due to different out-of-pocket caps for patients—$2,000 for self-administered drugs and $9,350 for IV treatments under Medicare Advantage, or no cap for traditional Medicare IVs—which can make SC options more expensive for health plans. While SC versions offer patient convenience and equivalent efficacy, Medicare plans are showing a preference for IV access to control costs, unlike commercial plans which have smaller coverage gaps.
Humana (NYSE:HUM) Price Target Lowered to $200.00 at Truist Financial
Truist Financial has lowered its price target for Humana (NYSE:HUM) from $285.00 to $200.00, maintaining a "hold" rating, which suggests an 8.32% upside from its current price. This revision follows several other firms, including Goldman Sachs and Leerink, also cutting their price targets for the insurance provider. Despite these adjustments, Humana slightly surpassed quarterly EPS estimates and reported robust revenue growth, and the company set its FY2026 guidance at 9.00 EPS.
UnitedHealth Group (NYSE:UNH) - Stock Analysis
This report provides a comprehensive stock analysis of UnitedHealth Group (NYSE:UNH), detailing its valuation, future growth prospects, past performance, financial health, dividend, management, and ownership. It includes analyst consensus, fair value estimates, recent news, and performance comparisons to the industry and market. Despite recent challenges, the company is seen by some as undervalued with long-term growth potential.
Spinal cord injury patients get new access as Aetna covers ReWalk exoskeleton
Lifeward (Nasdaq: LFWD) announced that Aetna has approved a prior authorization for a Medicare Advantage beneficiary to receive the ReWalk Personal Exoskeleton, deeming it medically necessary. This decision, following similar approvals from Humana and UnitedHealthcare, extends coverage for the ReWalk Personal Exoskeleton to approximately 16 million Medicare Advantage beneficiaries. The ReWalk Personal Exoskeleton is FDA-approved and backed by peer-reviewed studies highlighting its benefits for ambulation, musculoskeletal health, and cardiopulmonary function in individuals with spinal cord injuries.
Timber Creek Capital Management LLC Buys New Shares in UnitedHealth Group Incorporated $UNH
Timber Creek Capital Management LLC has acquired a new position of 6,449 shares in UnitedHealth Group (UNH) worth approximately $2.23 million in the third quarter. Institutional investors now own 87.86% of the stock, with other significant moves including Berkshire Hathaway's $1.57 billion stake. Despite recent price target cuts from some firms, Wall Street analysts maintain a "Moderate Buy" rating for UNH with an average target price of $372.13.
Aetna Joins Humana and United Healthcare in Expanding Medicare Advantage Coverage for ReWalk Personal Exoskeleton
Aetna has joined UnitedHealthcare and Humana in providing Medicare Advantage coverage for the ReWalk Personal Exoskeleton for eligible beneficiaries with spinal cord injuries. This expansion by three major insurers, covering approximately 16 million beneficiaries, signifies a significant step in recognizing the device's medical necessity and improving access to advanced rehabilitation technology. The ReWalk system, developed by Lifeward Ltd., is FDA-approved and has demonstrated benefits in ambulation, musculoskeletal health, and cardiopulmonary function, promoting independence and dignity for users.
Wall Street's Most Accurate Analysts Weigh In On 3 Health Care Stocks With Over 3% Dividend Yields
During volatile market conditions, dividend-yielding healthcare stocks like UnitedHealth Group, Viatris, and CVS Health can be attractive to investors due to their high free cash flows and regular payouts. This article highlights the ratings and price targets from top-performing analysts for these three companies. Analysts from Mizuho, Truist Securities, Piper Sandler, Barclays, B of A Securities, and JP Morgan have provided recent evaluations and price targets for these stocks, which each offer a dividend yield over 3%.
Zions Bancorporation National Association UT Reduces Stock Holdings in UnitedHealth Group Incorporated $UNH
Zions Bancorporation National Association UT significantly reduced its stake in UnitedHealth Group (UNH) by 76.0% in Q3, selling 13,936 shares and retaining 4,401 shares valued at approximately $1.52 million. Despite this, other major institutions like Geode Capital Management and Dodge & Cox substantially increased their positions, leading to 87.86% institutional ownership of UNH. Analysts maintain a "Moderate Buy" rating with an average price target of $372.13, even as recent price targets have been trimmed.
NEOS Investment Management LLC Raises Stock Holdings in UnitedHealth Group Incorporated $UNH
NEOS Investment Management LLC increased its stake in UnitedHealth Group (NYSE:UNH) by 44.3% in the third quarter, bringing its total holdings to 117,989 shares valued at over $40.7 million. Several other institutional investors also adjusted their positions in the healthcare conglomerate. Analyst ratings currently average a "Moderate Buy" for UnitedHealth Group, with an average price target of $372.13.
Mondrian Investment Partners LTD Makes New $105.91 Million Investment in UnitedHealth Group Incorporated $UNH
Mondrian Investment Partners LTD has made a new $105.91 million investment in UnitedHealth Group Incorporated (NYSE:UNH), acquiring 306,712 shares during the 3rd quarter, making it their 28th largest holding. UnitedHealth recently outperformed EPS estimates and reported strong revenue growth, with analysts maintaining a "Moderate Buy" consensus rating and an average price target of $372.13. Institutional investors hold a significant 87.86% of the stock.
